Literature DB >> 12071994

Squamous carcinoma of the external auditory canal: a different approach.

P P Knegt1, K W Ah-See, C A Meeuwis, L A van der Velden, J D F Kerrebijn, M F De Boer.   

Abstract

Squamous carcinoma of the external ear canal is a rare disease and a challenge to treat. Some controversy exists regarding the best options for treatment. Reported 5-year survival varies between 35% and 63%. Since 1976, we have adopted a conservative approach to these tumours, with patients undergoing a specific protocol of meticulous tumour debulking followed by a course of repeated topical 5-fluoro-uracil (5-FU) cream application and necrotectomy. Data was collected prospectively. From 1976 to 1998, 23 patients underwent primary treatment according to our protocol. Nine patients had T1 disease whereas six had T2 and eight had T3 disease. The 5- and 10-year overall survivals were 74% and 60% respectively. These results compare very favourably with those in the literature and surgical debulking with topical 5-FU and necrotectomy remains our primary treatment of choice for squamous cell carcinoma of the external auditory canal.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12071994     DOI: 10.1046/j.1365-2273.2002.00561.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  3 in total

1.  Predictors of survival and recurrence after temporal bone resection for cancer.

Authors:  Luc G T Morris; Saral Mehra; Jatin P Shah; Mark H Bilsky; Samuel H Selesnick; Dennis H Kraus
Journal:  Head Neck       Date:  2011-09-23       Impact factor: 3.147

2.  Bilateral external auditory canal squamous cell carcinoma: a case report.

Authors:  Cağdaş Elsürer; Hilmi Alper Senkal; Ehab Zayyan; Taner Yilmaz; Sefa Kaya
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-03-15       Impact factor: 2.503

3.  Squamous cell carcinoma of the external auditory canal.

Authors:  David Lobo; José L Llorente; Carlos Suárez
Journal:  Skull Base       Date:  2008-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.